PHILADELPHIA -- The University of Pennsylvania's Institute for Translational Medicine and Therapeutics' 9th Annual International Symposium (ITMAT), Progress in Translational Science: Emerging Therapeutic Modalities, will be held on October 13-14. The symposium will feature outstanding speakers from the United States and abroad to address topics at the core of translational science. Speakers will include experts researching advances in stem cell biology, single cell metabolomics, and infectious diseases.
Date: Monday and Tuesday, October 13 - 14, 2013, starting at 8:30 am.
Location: Smilow Center for Translational Research, Rubenstein Auditorium and Lobby, 3400 Civic Center Blvd, Philadelphia, PA 19104
The symposium will feature presentations in six major areas:
- Challenges and Opportunities in Translational Research
- Stem Cell Therapeutics
- Movement in Malaria
- Focus on the Single Cell
- Variability in Drug Response
- Translational Immunology
Garret A. FitzGerald, MD, Director of ITMAT, will host the event. Speakers and talks include:
- Kenneth S. Zaret, PhD, Joseph Leidy Professor of Cell and Developmental Biology, Perelman School of Medicine, University of Pennsylvania, Discovering networks and diagnostics for pancreatic cancer progression
- Clifford J. Woolf, MB, BCh, PhD, Director, F.M. Kirby Neurobiology Center and Program in Neurobiology, Boston Children's Hospital, Professor of Neurology and Neurobiology, Harvard Medical School, Studying neurodegenerative disease in a dish
- Elaine Fuchs, PhD, Rebecca C. Lancefield Professor, HHMI, The Rockefeller University, Stem cells in homeostasis and cancer
- Beatrice H. Hahn, MD, Professor, Departments of Medicine and Microbiology, Perelman School of Medicine, University of Pennsylvania, Ape reservoirs of human malaria
- Jim Eberwine, PhD, Elmer Holmes Bobst Professor, Co-Director of the PENN Genome Frontiers Institute, Department of Pharmacology, Perelman School of Medicine, University of Pennsylvania, Single cell parables: Heterogeneity informs translational considerations
- Romina Goldszmid, PhD, Staff Scientist, Laboratory of Experimental Immunology, Cancer and Inflammation Program, Center for Cancer Research, NCI, NIH, The role of the microbiome in response to cancer therapy
- Paul Watkins, MD, Hamner-University of North Carolina Institute for Drug Safety Sciences, Why good drugs are sometimes bad for the liver - from man to mouse to computer
Carl H. June, MD, Richard W. Vague Professor in Immunotherapy, Program Director of Translational Research, Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Driving CARs for cancer: are we there yet?
For additional details and presentation times, visit the 2014 Full Agenda.
Funding for this conference was made possible in part from the National Center for Advancing Translational Sciences.
Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $4.3 billion enterprise.
The Perelman School of Medicine has been ranked among the top five medical schools in the United States for the past 17 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $392 million awarded in the 2013 fiscal year.
The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania -- recognized as one of the nation's top "Honor Roll" hospitals by U.S. News & World Report; Penn Presbyterian Medical Center; Chester County Hospital; Penn Wissahickon Hospice; and Pennsylvania Hospital -- the nation's first hospital, founded in 1751. Additional affiliated inpatient care facilities and services throughout the Philadelphia region include Chestnut Hill Hospital and Good Shepherd Penn Partners, a partnership between Good Shepherd Rehabilitation Network and Penn Medicine.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2013, Penn Medicine provided $814 million to benefit our community.